证券代码：002166 证券简称：莱茵生物 桂林莱茵生物科技股份有限公司 投资者关系活动记录表 编号：2025-003 | | □特定对象调研 □分析师会议 | | --- | --- | | □媒体采访 | □业绩说明会 | | 投资者关系活动 □新闻发布会 | □路演活动 | | 类别 □现场参观 | | | 其他 ☑ | 线上交流 | | 参与单位名称及 | 浙商证券杨骥、杜宛泽、隋牧含，天风证券戴飞、马裕洲，华鑫证券张 | | | 倩，华福证券童杰，东方证券王树娟，德福资本王晓彤、桑淼，杭州巨 | | 人员姓名 | 子私募基金张立烽，Pleiad Investment Advisors Limited Simon Sun | | 时间 年 2025 | 月 日 8 29 | | 地点 公司 | | | 上市公司接待人 | 副总经理兼董事会秘书 罗华阳 | | 员姓名 | | | | 一、董事会秘书介绍 2025 年上半年经营情况与业绩情况。 | | | 二、问答交流 | | | 问题一、请问公司核心大单品罗汉果和甜叶菊今年原材料收购价格 | | | 变化情况。以及如何看待往后产品的价格变化趋势？ | ...

Core Viewpoint - The company, Guilin Rhine Biotechnology Co., Ltd., is reducing the investment scale of certain fundraising projects and will permanently supplement its working capital with the remaining funds from these projects [2][10]. Fundraising Overview - The company raised a net amount of approximately 961.11 million RMB from a non-public stock issuance, which was approved by the China Securities Regulatory Commission [2]. - The funds were deposited in a dedicated account, and the management of these funds adheres to relevant regulations to ensure proper usage [3]. Fund Management and Usage - As of July 31, 2025, the total balance in the fundraising account was 1.63 million RMB, with a total interest income of approximately 1.48 million RMB [3]. - The company has directly invested approximately 652.66 million RMB into various projects, including 573.96 million RMB for the Stevia Extraction Factory and 78.70 million RMB for the Rhine Natural Health Products Research Institute [3][4]. Project Completion and Fund Reduction - The Stevia Extraction Factory project has met the completion criteria, with a total investment of 573.96 million RMB, leaving a surplus of approximately 36.32 million RMB [7][9]. - The Rhine Natural Health Products Research Institute project has been partially completed, with 78.70 million RMB invested and an estimated remaining payment of 37.08 million RMB [8][9]. Impact of Fund Reduction - The decision to reduce the investment scale and reallocate surplus funds is aimed at enhancing the company's liquidity and financial structure, thereby supporting sustainable development and maximizing shareholder value [10][9]. - The company’s current research and development capabilities are deemed sufficient to support ongoing business operations and future product innovations [9]. Approval Process - The board of directors and the supervisory board have approved the proposal to reduce the investment scale and reallocate surplus funds, which will be submitted for shareholder approval [10][11].